We are a biopharmaceutical company specializing in two high-growth markets: assisted reproductive drugs and ophthalmic drugs. Targeting unmet clinical needs, we have built a comprehensive R&D system and internal production capabilities at a commercial scale. Leveraging these resources, we have independently developed a diverse product pipeline and advanced several high-tech, commercially promising drug candidates in both fields to late-stage clinical trials and the commercialization stage.
Our founder and CEO, Dr. Peng Hongwei, brings over 30 years of expertise in biopharmaceutical R&D. Notably, Dr. Peng contributed to the groundbreaking scientific achievement, “Mechanism of Tumor Angiogenesis and its Application in Anti-Angiogenesis Therapy,” which earned the prestigious National Science and Technology Progress Award (First Class) (国家科技进步一等奖). Dr. Peng also spearheaded the development of the national Category 1 biologic drug, recombinant human brain natriuretic peptide (brand name: Xinhuosu® (新活素®)), which received market approval in 2005. This product has been a unique offering in the domestic market for nearly 20 years and has been recommended as a first-line treatment in the National Acute Heart Failure Treatment Guidelines. This innovation has also been recognized with accolades such as the Sichuan Provincial Science and Technology Progress Award (First Class) (四川省科技进步一等奖), further underscoring its clinical and scientific significance. His proven leadership and track record in guiding innovative biopharmaceutical products from early development to commercialization provide a strong foundation for our success.
